Repare Therapeutics Doses First Subject in Phase I Solid Tumour Trial
LifeSci Capital Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $8
Repare Begins Clinical Trial Combining RP-3467 and PARP Inhibitor Olaparib to Fight Advanced Cancers
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor
Express News | Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of Rp-3467, a PolΘ Atpase Inhibitor
Q3 Pharma and Biotech Layoffs in Charts: More Than 1000 Each in July and August